Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Strides Pharma Science Ltd ( (IN:STAR) ) is now available.
Strides Pharma Science Ltd reported its highest-ever quarterly earnings per share (EPS) for Q2FY26, with an operational profit after tax (PAT) of ₹1,403 million and an EPS of ₹15.2, marking an 84% year-on-year growth. The company’s strong performance was driven by a 4.6% increase in revenue to ₹12,208 million and a significant improvement in gross and EBITDA margins, reflecting its focus on profitability and financial discipline amidst currency challenges and ongoing capital expenditures.
More about Strides Pharma Science Ltd
Strides Pharma Science Ltd is a global pharmaceutical company headquartered in Bengaluru, India, and is listed on the BSE Limited and National Stock Exchange of India Limited. The company primarily operates in regulated markets and follows an ‘in Africa for Africa’ strategy, along with an institutional business to service donor-funded markets. Strides has global manufacturing sites in India, Italy, Kenya, and the United States, focusing on ‘difficult to manufacture’ products sold in over 100 countries.
Average Trading Volume: 15,274
Technical Sentiment Signal: Buy
Current Market Cap: 78.34B INR
For a thorough assessment of STAR stock, go to TipRanks’ Stock Analysis page.